Further testing of the clinical candidate SCH900776 and other specific Chk1 inhibitors in B-cell malignancies, including CLL, seems warranted and can be particularly appropriate for TP53-mutated or fludarabine-refractory patients. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.